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Retinal endothelial cells (REC) likely contribute to the clearance of intravitreally injected IgG. Because this
is of high relevance to the pharmacokinetic assessment of the widely used therapeutic Fc fusion protein
aﬂibercept, we studied its transport through immortalized bovine REC (iBREC) in detail. For shuttling of
IgG or Fc fusion proteins like aﬂibercept, endothelial cells use the highly conserved neonatal Fc receptor
(FcRn) also expressed in iBREC where it is down regulated by serum depletion. Therefore, we focused on
studying intracellular localization and transport of aﬂibercept under conditions affecting its interaction
with the FcRn. Intracellular localization of aﬂibercept was assessed by Western-blot analyses of sub-
cellular protein fractions or by immunoﬂuorescence staining. After uptake in a temperature-dependent
process, aﬂibercept co-localized with early endosomes, which harbor FcRn. Similar amounts of aﬂi-
bercept were co-extracted with proteins from membranes/organelles irrespectively of the amount of FBS
in the culture medium. Lowering the concentration of FBS resulted in a strong, but reversible association
with cytoskeletal proteins suggesting a block in intracellular transport. In accordance with this ﬁnding,
aﬂibercept's transport through an iBREC monolayer grown on porous membrane inserts was markedly
delayed in the absence of FBS in the culture medium indicating that aﬂibercept is taken up but not
exocytosed under these conditions. Transcytosis of aﬂibercept was also strongly delayed by inhibition of
phosphatidylinositol 3-kinase with LY294002, which affects FcRn-mediated IgG transport. A similar
inhibition of aﬂibercept's transport was observed with IgG-binding proteins (i.e. protein A or protein G)
that block interaction between FcRn and aﬂibercept. Interfering with aﬂibercept's binding to the FcRn
with protein A (or protein G) or the inhibitory FcRn-speciﬁc monoclonal antibody 1G3 resulted in a
reduced amount of intracellular aﬂibercept. Taken together, our results strongly suggest that FcRn is
involved in transport of aﬂibercept through REC in vitro.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Pathogeneses of diabetic retinopathy, retinal vein inclusion and
age related macular edema are associated with de-regulated
expression of various cytokines including the most relevantarly endosome antigen 1; Fc,
, fetal bovine serum; (i)BREC,
nase, phosphatidylinositol 3-
buffered saline without Ca2þ
cells; RPE, retinal pigment
othelial growth factor (A).
(H.L. Deissler).
Ltd. This is an open access article uvascular endothelial growth factor A (VEGF-A). Accordingly, VEGF-
binding proteins ranibizumab, aﬂibercept and bevacizumab are
now widely used to treat these conditions, and their VEGF-
inactivating activities were clearly conﬁrmed by in vitro studies
with retinal endothelial cells (REC) (Presta et al., 1997; Holash et al.,
2002; Ferrara et al., 2006, Arevalo et al., 2011, Do et al., 2012; Lang
et al., 2013; Deissler et al., 2008, 2011, 2012, 2014; Stewart et al.,
2011). The pharmacokinetic proﬁles of therapeutic IgG, their de-
rivatives and fragment crystalisable (Fc) fusion proteins are deter-
mined by their clearance from the eye, a process inwhich REC seem
to play a role (Kim et al., 2009; Julien et al., 2014). We have recently
shown that immortalized endothelial cells of the bovine retina
(iBREC) can take up the humanized VEGF-binding antibody bev-
acizumab and transport it through the monolayer or release it fromnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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IgG with the neonatal Fc receptor (FcRn) impaired transport of
bevacizumab and affected its subcellular localization in these cells
(Deissler et al., 2016). FcRn, which is expressed in various ocular
structures including the retinal endothelium, is primarily involved
in transcytosis and recycling of IgG and albumin in endothelial cells
of various origins and responsible for maintaining homeostasis of
these proteins in the serum (Kim et al., 2008; Powner et al., 2014;
Junghans and Anderson, 1996; Ward et al., 2003). This receptor is
a dimer consisting of two not covalently linked subunits: b2-
microglobulin and a larger polypeptide related to major histo-
compatibility complex class I proteins (Junghans and Anderson,
1996). In early endosomes, which are characterized by the
expression of the early endosome antigen 1 (EEA1), the FcRn binds
IgG and albumin independently from each other at pH 6. The
complexes are then shuttled away from the lysosomes and both
proteins are released by exocytosis at physiological pH (Junghans
and Anderson, 1996; Ward et al., 2003, 2005; Ober et al., 2004;
Goebl et al., 2008; Jerdeva et al., 2010, Sand et al., 2015). Inter-
fering with vesicle formation by blocking phosphatidylinositol 3-
kinase (PI3-kinase) with LY294002 or Wortmannin strongly abol-
ished FcRn-mediated IgG transport in rat kidney epithelial cells
expressing FcRn (McCarthy et al., 2000). The human and bovine
homologues of FcRn are highly conserved, and it was conﬁrmed in
several studies that human IgG is indeed efﬁciently bound, trans-
ported and released in the transcytosis pathway by bovine FcRn
(Ober et al., 2001; Kacskovics et al., 2000, 2006; Cui et al., 2014).
Expression of the FcRn in iBREC is exclusively associated with
proteins from the membrane/organelle fraction, is weaker in the
absence of FBS but not affected by bevacizumab. Most interestingly,
transport of bevacizumab through an iBREC monolayer is retarded
in the absence of FBS accompanied by its accumulation in the
fraction of cytoskeleton proteins (Deissler et al., 2016). iBREC also
take up aﬂibercept, which consists of binding domains of VEGF
receptors and the human IgG1 Fc domain, within a few hours after
exposure, and the Fc fusion protein is then mainly localized in a
perinuclear region (Holash et al., 2002; Deissler et al., 2014). These
observations invited the hypothesis that binding to FcRnmight also
be involved in aﬂibercept's intra- and transcellular transport and
we therefore studied uptake and transport of aﬂibercept under
conditions affecting its potential interaction with FcRn.2. Materials and methods
2.1. Aﬂibercept and antibodies
Eylea (40 mg/ml aﬂibercept) was a kind gift from Bayer Vital
GmbH (Leverkusen, Germany) (Holash et al., 2002; Do et al., 2012).
Goat polyclonal detection antibodies (F(ab0)2, labelled with AlexaTable 1
Antibodies used in study.
Target Speciﬁcity Host Source
FcRn (large chain) human, bovine rabbit, polyclonal bio-techne
FcRn (heterodimer) human mouse, monoclonal Genetex (B
EEA1 human, bovine rabbit, polyclonal abcam (Ca
claudin-1 human, bovine rabbit, polyclonal Thermo Sc
actin human, bovine mouse, monoclonal abcam, AC
IgG, g-chain human goat, polyclonal, coupled to HRPa Thermo Sc
whole IgG rabbit goat, polyclonal, coupled to HRPa Biorad (Mu
whole IgG mouse goat, polyclonal, coupled to HRPa Biorad, 170
a HRP: horseradish peroxidase.Fluor 594/488) were from Thermo Scientiﬁc (Karlsruhe, Germany);
other antibodies are listed in Table 1.2.2. General information on cell culture, treatment of iBREC with
effectors and transcytosis assay
Only general information is provided here, because the current
study is based on an approach already described in great detail
(Deissler et al., 2016). Conﬂuent monolayers of telomerase-
immortalized bovine microvascular REC (iBREC) established after
cultivation for at least 4 d were used in all experiments, which were
repeated at least twice (Deissler et al., 2005, 2008, 2011, 2016). In
control experiments, cells were processed identically in medium
only lacking the effector(s) under investigation. A ﬁnal concentra-
tion of 250 mg/ml (~2 mM) aﬂibercept - achievable by intravitreal
injection - was always used.
To study the effect of FBS on internalization or transport of
aﬂibercept, iBREC were incubated with culture medium containing
0%,1% or 5% FBS for 24 h before they were exposed to aﬂibercept for
up to 1 d (Deissler et al., 2014, 2016). Potential competitive effects of
Fc-binding proteins (i.e. protein A and protein G; Thermo Scientiﬁc)
on the internalization or transport of aﬂibercept were explored as
described (Raghavan et al., 1994; Deissler et al., 2016). To prevent
interaction of aﬂibercept with FcRn, iBREC were pre-treated with
10 mg/ml of mouse monoclonal antibody (MAb) 1G3 for 1 h before
aﬂibercept was added for additional 4 h. Whole cell extracts and
subcellular fractions, i.e. proteins localized in the cytoplasm, in
membranes/organelles, and components of the cytoskeleton, were
prepared from fresh or frozen cell pellets as described in detail
elsewhere (Deissler et al., 2012, 2014, 2016).
Transcytosis assays to assess transport of aﬂibercept from the
lower to the upper chamber through a conﬂuent iBREC monolayer
cultivated on membrane inserts (4.7 cm2, pore size 0.4 mm; Corn-
ing) were performed as published (Antohe et al., 2001; Deissler
et al., 2016). The effect of inhibition of PI3-kinase on aﬂibercept
transport was evaluated by adding LY294002 (500 nM in 0.01%
dimethyl sulfoxide (DMSO); Sigma-Aldrich, Dreieich, Germany) to
both chambers. After pre-treating iBREC for 2 h, aﬂibercept was
placed in the bottom chamber and samples were then taken from
the upper chamber.
All Western blot analyses were performed under reducing con-
ditions; equal amounts of protein were loaded per lane when cell
extracts (~25 mg) or fractions thereof (~5 mg) were analyzed (Deissler
et al., 2012, 2014). To determine the amount of transported aﬂi-
bercept, the sample (75 ml) taken from the supernatant in upper
chamber (total volume: 1.5 ml) was directly analyzed by Western
blot without further processing; 0.1% of the supernatant was loaded
per lane (Deissler et al., 2016). Western blot analyses were repeated
at least twice; a typical image is shown. Observed differencesConcentration
(Wiesbaden, Germany), NBP1-89127 Western blot analysis: 3 mg/ml
immunoﬂuorescence staining: unspeciﬁc
iozol, Eching, Germany), 1G3 functional assay: 10 mg/ml
mbridge, UK), ab137403 Western blot analysis: 70 ng/ml,
immunoﬂuorescence staining: 20 mg/ml
ientiﬁc, JAY.8 Western blot analysis: 100 ng/ml
JAY.8 does not cross react with claudin-3
-40 Western blot analysis: 500 ng/ml
ientiﬁc, 628420 Western blot analysis: 1:20000
nich, Germany), 170-5046 Western blot analysis: 1:30000
-5047 Western blot analysis: 1:20000
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reproducible and resulted in contrasting chemiluminescence sig-
nals. Subsequent quantiﬁcation of chemiluminescence signals
would not have gained any additional insight.
Immunoﬂuorescence staining of conﬂuent iBREC monolayers
was carried out as previously described (Deissler et al., 2014, 2016).
Aﬂibercept-positive cells were quantiﬁed by counting cells immu-
nostained with the antibody binding to human IgG in four different
microscopic ﬁelds divided by the number of cell nuclei therein.
2.3. Measurement of cell index
To assess cell viability or barrier function of iBREC in the pres-
ence of aﬂibercept under different serum conditions, electric cell-
substrate impedance measurements were performed using the
microelectronic biosensor system for cell-based assays xCELLigence
RTCA DP (Acea, OLS, Bremen, Germany) (Sun et al., 2012). Imped-
ance was measured between electrodes in an individual well of an
E-Plate VIEW 16 PET (Acea) and calculated as the unit-free
parameter cell index (CI) according to the formula CI¼(ZiZ0)/
15U where Zi is the impedance measured at an individual time
point and Z0 the impedance measured at start of the experiment.
100 ml culture mediumwere placed in each well of an E-Plate VIEW
16 PET (coated overnight with 50 mg/ml ﬁbronectin at 4 C) and
plates were equilibrated at 37 C in the incubator for at least 1 h
before backgroundmeasurements were performed.1.2 104 iBREC
in 100 ml were seeded per well and cell indexwas determined every
15 min for the ﬁrst 24 h and afterwards every 1 h until a stable
value of CI z 20 was reached 3 d after seeding indicating a stable
conﬂuent monolayer. Culture medium was replaced by medium
with or without FBS and CI was monitored for additional 24 h
before aﬂibercept (ﬁnal concentration: 250 mg/ml) was added.
Subsequently, CI was measured every 15 min for up to 48 h and
values were normalized in relation to those measured immediately
before addition of aﬂibercept. Similar experiments were carried out
in the presence of LY294002 (ﬁnal concentration: 50, 500 and
5000 nM) to assess its inﬂuence on barrier stability.
3. Results
3.1. Subcellular localization and transcytosis of aﬂibercept strongly
depend on presence of serum
Because expression of the FcRn is regulated by serum compo-
nents in iBREC (see also Fig. 1A), we investigated the effects of FBS
on aﬂibercept's subcellular localization, its transport through an
iBREC monolayer (/ transcytosis), as well as its transporting back
to the same cell side it came from (/ recycling).
Irrespective of the serum concentration, internalized aﬂibercept
was found to be associated with proteins from membranes or or-
ganelles (Fig. 1A) as shown by Western blot analyses of subcellular
fractions prepared 4 or 24 h after its addition to iBREC pre-
incubated with 0e5% FBS for 1 d. A vast amount of aﬂibercept
taken up by iBREC was co-extracted with cytoskeletal proteins (e.g.
actin, vimentin) only when cells were exposed to lower FBS con-
centrations (0% or 1%; Fig. 1A). Aﬂibercept did not affect viability of
iBREC - assessed by cell index measurements - at either concen-
tration of FBS (data not shown). Immunoﬂuorescence staining
revealed that about 50% of iBREC had internalized aﬂibercept
irrespectively of the FBS concentration in the culture medium
(aﬂibercept-positive cells: 52% ± 12% after cultivation with 5% FBS
versus 56% ± 10% without FBS, p > 0.05). Aﬂibercept was localized
in small isolated clusters or spots close to the nucleus when iBREC
had been cultivated without FBS (Fig. 3, red arrowheads) whereas it
was more homogenously distributed in a perinuclear region aftercultivation in the presence of 5% FBS (Fig. 3, yellow arrowheads).
FBS-dependent accumulation of aﬂibercept in the subcellular
fraction of cytoskeleton proteins was shown to be reversible: When
iBREC were treated for 1 d with aﬂibercept in mediumwith 1% FBS
before the serum concentration was increased to 5% for another
day, the amount of aﬂibercept associated with cytoskeleton pro-
teins decreased substantially during cultivation with more FBS
(Fig. 1B).
To assess aﬂibercept's transport through an iBREC monolayer
cultivated on porousmembrane inserts (/ transcytosis), cells were
exposed to 0 or 5% FBS for 24 h in both chambers before aﬂibercept
was added to the lower chamber for up to 2 d (Fig. 1C). Aﬂibercept
was always placed in contact to the basal cell membrane because
after intravitreal injection the basal side of the REC layer of the
vessel walls is primarily exposed to the drug. Samples were taken
from the upper chamber (above the apical cell membrane) at
various time points (Fig. 1C) to determine the amounts of aﬂi-
bercept released into the medium by Western blot analyses. In
accordance with aﬂibercept's accumulation in the fraction of
cytoskeleton proteins in the absence of serum, its transport by cells
in medium without FBS was much slower compared to 5% FBS
(Fig. 1C) suggesting a block in intracellular transport under these
conditions. In addition to transcytosis, internalized aﬂibercept
might also be recycled to the compartment it came from. To study
the relevance of this transport route, iBREC were ﬁrst exposed to
aﬂibercept in the lower chamber in medium with 5% FBS for 24 h
after which a considerable amount of the protein was detected in
the upper chamber as a consequence of uptake and transport
through the monolayer. However, during subsequent cultivation of
the thoroughly washed cells in aﬂibercept-free medium for addi-
tional 24 h, only a very small amount of aﬂibercept was recycled to
the lower chamber (data not shown). When medium containing
only 1% FBS was used, recycling of aﬂibercept was not observed at
all.
3.2. Uptake of aﬂibercept by iBREC is temperature-dependent
Possible involvement of FcRn in uptake and intracellular trans-
port of aﬂibercept by iBREC requires vesicle-based trafﬁcking,
which is known to be slowed down at lower temperature.
Accordingly, the amount of internalized aﬂibercept was lower
when the cells were temporarily cultivated at 4 C (Fig. 2A). That
the tight iBREC barrier was not affected by the temperature switch
was conﬁrmed by measuring the strong and stable expression of
the tight junction (TJ)-protein claudin-1. Presence of claudin-1
strongly correlates with a stable barrier in iBREC (Deissler et al.,
2013).
3.3. Inhibition of PI3-kinase delays transcytosis of aﬂibercept
through an iBREC monolayer
To investigate whether blocking PI3-kinase activity affects aﬂi-
bercept's transport, iBREC cultivated on porous membrane inserts
were exposed to 500 nM LY294002 for 2 h before aﬂibercept was
added to the lower chamber. Under these conditions, the iBREC
barrier was stable over several days; higher concentrations resulted
in barrier dysfunction (data not shown). Pre-treating of iBREC with
LY294002 indeed strongly inhibited transcytosis of aﬂibercept
(Fig. 2B), but changes in aﬂibercept's uptake - amount and intra-
cellular localization - were not evident (data not shown).
3.4. Intracellular aﬂibercept is associated with EEA1-positive
vesicles
The above-mentioned results suggested that aﬂibercept's
Fig. 1. Subcellular localization and transcytosis of aﬂibercept are serum-dependent. (A) Conﬂuent iBREC pre-incubated for 24 h with medium containing 0e5% FBS were treated
with aﬂibercept before subcellular fractions were prepared 4 or 24 h later. These were analyzed by Western blot to determine internalized aﬂibercept and presence of FcRn. Similar
amounts of aﬂibercept were co-extracted with membrane proteins, irrespectively of the FBS concentration in the culture medium. In contrast, very strong aﬂibercept-speciﬁc bands
assigned to the fraction consisting of cytoskeleton proteins were observed only after cultivation in serum-reduced media. iBREC expressed FcRn when cultivated in medium with
serum, but only weak FcRn-speciﬁc bands were seen when membrane/organelle fractions of cells kept without serum for some time were analyzed. Aﬂibercept did not affect FcRn
expression. (B) Accumulation of aﬂibercept in the cytoskeleton fraction is reversible: Conﬂuent iBREC were treated with aﬂibercept for 2 d in medium with 1% or 5% FBS, or in
medium with 1% FBS for 1 d before FBS was increased to 5% for another day. After incubation with 1% FBS, most of the aﬂibercept was found in the fraction containing cytoskeleton
proteins and this portion strongly decreased when the FBS concentration was brought to 5%. (C) Conﬂuent iBREC cultivated on porous membrane inserts were treated as described
in (A) before aﬂibercept was added to the lower chamber. Subsequently its transport through the iBREC monolayer (þiBREC) or its diffusion through cell-free membrane inserts
(-iBREC) were monitored by Western blot analyses of samples from the top chamber. Transport of aﬂibercept through the iBREC monolayer was strongly promoted by FBS whereas
its diffusion through membranes without cells was not affected.
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aﬂibercept in EEA1-positive early endosomes was studied. iBREC
treated with aﬂibercept for 4 h (with or without FBS) were stained
with antibodies against EEA1 in combination with visualization of
aﬂibercept. The uniform EEA1-speciﬁc staining seen after cultiva-
tion in medium with 5% FBS clearly co-appeared with signals
indicating internalized aﬂibercept, particularly in areas close to the
nucleus (Fig. 3, yellow arrow). However, a mosaic pattern rather
than overlapping staining of aﬂibercept and EEA1 was observed in
these regions of cells cultivated without FBS (Fig. 3, red arrows).
Western blot analyses of subcellular fractions conﬁrmed that
exposure to aﬂibercept did not alter expression of EEA1 (data not
shown).
3.5. Protein A and protein G retard aﬂibercepts's transcytosis and
affect its intracellular localization
If binding of aﬂibercept to FcRnwas involved at some stage of its
uptake and intracellular trafﬁcking, preventing the interaction of
the Fc domain of the fusion protein with FcRn should alter its
transport through an iBREC monolayer and its subcellular locali-
zation. Protein A or protein G were considered useful tools because
they compete with the FcRn for binding of the IgG1 Fc part
(Raghavan et al., 1994; Wines et al., 2000). In transcytosis assays
performed in the presence of an excess of one of the IgG-bindingproteins for 6 h, protein A (5 Fc terminus-binding sites, 10 mM) or
protein G (2 Fc terminus-binding sites, 25 mM) markedly delayed
transport of aﬂibercept (Fig. 4A). Western blot analyses of subcel-
lular fractions prepared 4 h after addition of aﬂibercept to iBREC
showed that aﬂibercept was localized in the fractions of membrane
and cytoskeletal proteins (Fig. 4B). However, when binding of
aﬂibercept to FcRn was impaired by protein A or protein G, the Fc
fusion protein was no longer co-extracted with proteins from
membranes and organelles. Their moderate excess (z10 Fc-
binding sites) resulted in an overall reduced amount of intracel-
lular aﬂibercept; in the presence of a larger excess (z50 Fc-binding
sites) aﬂibercept was co-extracted only with cytoskeleton proteins
(Fig. 4B). FcRn expression was not altered by protein A/G (data not
shown).3.6. FcRn-speciﬁc antibody 1G3 reduces amount of internalized
aﬂibercept
Binding of MAb 1G3 to the FcRn heterodimer blocks interaction
of other IgG with this receptor (Raghavan et al., 1994). As expected,
less aﬂibercept was present in iBREC pre-treated with 1G3 for 1 h
before addition of the Fc fusion protein (Fig. 4C).
Fig. 2. Temperature-dependent internalization and retardation of its transport by
PI3-kinase inhibition is indicative of an active uptake of aﬂibercept by iBREC. (A)
Conﬂuent iBREC were incubated with aﬂibercept for 4 h at 4 C or 37 C before cellular
extracts were prepared and analyzed. More aﬂibercept was taken up by iBREC kept at
37 C. Actin was assessed as loading control and strong expression of the TJ-protein
claudin-1 conﬁrmed stability of the tight barrier. (B) iBREC grown on porous mem-
brane inserts were pre-treated with LY294002 or 0.02% DMSO (vehicle) for 2 h present
in both chambers. Aﬂibercept was then added to the lower chamber and samples taken
from the upper chamber were analyzed by Western blot. Inhibition of PI3-kinase
delayed transcytosis of aﬂibercept.
Fig. 3. Aﬂibercept is associated with early endosomes. iBREC cultivated for 24 h in
media containing 0% or 5% FBS were treated with aﬂibercept for additional 4 h, and
aﬂibercept (red) or early endosome-speciﬁc EEA1 (green) were visualized by immu-
noﬂuorescence staining. Variation of the FBS concentration resulted in different pat-
terns of aﬂibercept- and EEA1-staining: After cultivation of iBREC without FBS,
aﬂibercept localized to small clusters or spots close to the nucleus (red arrowheads)
and these did not overlap with the EEA1-positive endosomes (red arrows). In cells
cultivated with 5% FBS, the perinuclear aﬂibercept-speciﬁc staining as well as that of
EEA1 were more homogenous (yellow arrowheads), and co-localization of aﬂibercept
and EEA1 was evident (yellow arrow).
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Involvement of the Fc-binding transporter/receptor FcRn in
uptake of aﬂibercept by iBREC and its transition through these cells
was investigated because of solid evidence indicating that intra-
vitreally injected therapeutic IgG or related proteins are e at least
to some extent - cleared from the eye via retinal capillaries (Kim
et al., 2009). Accordingly, aﬂibercept was detected in retinal ves-
sels in the monkey eye one day after intravitreal injection (Julien
et al., 2014).
Although smaller than an IgG, aﬂibercept is still too large to pass
through the very small intercellular gaps between individual cells
of the unchallenged retinal endothelium (Hofman et al., 2000).
Therefore, aﬂibercept's transition is most likely a consequence of an
active transport mediated by receptors and vesicles. An obvious
candidate receptor, typically involved in such processes and bind-
ing to the Fc domain of an IgG or Fc fusion protein, is the trans-
porter/receptor FcRn (Junghans and Anderson, 1996; Ward et al.,
2003; Ober et al., 2004; Goebl et al., 2008; Kim et al., 2008;
Powner et al., 2014).
To study transcytosis and uptake of aﬂibercept under conditions
potentially affecting its interaction with the FcRn, we used the
established iBREC cell culture model. In accordance with our pre-
vious ﬁndings that aﬂibercept is taken up by iBREC without
affecting their barrier function, it is efﬁciently transported through
an iBREC monolayer (Deissler et al., 2014). Internalized amounts of
aﬂibercept were markedly lower when cells were cultivated at 4 C
instead of 37 C, supporting our hypothesis that non-speciﬁcendocytosis and active vesicle-based transport are involved,
whereas paracellular passage might play no more than a minor
role. Accordingly, most of the internalized aﬂibercept was co-
extracted with proteins from membranes and organelles, and it
was also detected in EEA1-positive early endosomes, the organelles
in which the FcRn is mainly localized (Ward et al., 2003, 2005;
Jerdeva et al., 2010). However, FcRn could not directly be immu-
nostained with the available speciﬁc antibody directed against the
heavy chain of the receptor; visualization of a putative interaction
between aﬂibercept and FcRn was therefore not possible (Powner
et al., 2014; Deissler et al., 2016). Interfering with vesicle forma-
tion by inhibiting PI3-kinase also markedly affected transport of
aﬂibercept whereas intracellular amount and localization were not
obviously altered. These ﬁndings suggest that aﬂibercept is taken
up and then degraded under these conditions. In epithelial cells of
the rat kidney, PI3-kinase blocking only affected FcRn-mediated
transport, supporting our hypothesis that FcRn is indeed involved
in aﬂibercept transport in iBREC (McCarthy et al., 2000).
Transcytosis of aﬂibercept was most efﬁcient in the presence of
substantial amounts of FBS when amongst other things the FcRn is
strongly expressed by iBREC. A similar serum-dependent transport
was observed in analogous experiments with the IgG bevacizumab,
suggesting that the Fc domain plays a crucial role in intracellular
transport of such macromolecules (Deissler et al., 2016). The
importance of an aﬂibercept-FcRn interaction for intracellular
transport was further supported by our observation that uptake
and transcytosis of aﬂibercept was inhibited by IgG-binding pro-
teins A and G, again in complete accordance with similar effects
reported for bevacizumab (Deissler et al., 2016). Binding sites for
Fig. 4. Transcytosis, subcellular localization and internalization of aﬂibercept are affected when its binding to FcRn is blocked. (A) Aﬂibercept with or without an IgG-binding
protein was added to the lower chamber and its transport through the iBREC monolayer (þiBREC) or its diffusion through cell-free membrane inserts (-iBREC) was monitored by
Western blot analyses of samples from the top chamber. Transport of aﬂibercept (þiBREC) was markedly slowed down by an excess of protein A or protein G whereas its free
diffusion (- iBREC) was not. (B) Subcellular fractions of conﬂuent iBREC treated as described in (A) for 4 h were analyzed by Western blot. When protein A or protein G had been
present in the culture medium, aﬂibercept was no longer co-extracted with membrane proteins but detected in the fraction of cytoskeleton proteins. (C) iBREC pre-treated with
FcRn-speciﬁc MAb 1G3 were exposed to aﬂibercept for 4 h before cellular extracts were prepared. Western blotting revealed that less aﬂibercept is present in iBREC when binding to
FcRn is blocked by 1G3.
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regions of the Fc terminus of human IgG1 (or aﬂibercept) overlap
with those of the FcRn, whereas other known Fc receptors bind to
different regions of a human IgG1 (Deisenhofer, 1981; Raghavan
et al., 1994; Burmeister et al., 1994; Sauer-Eriksson et al., 1995;
Wines et al., 2000). Moreover, pre-treating iBREC with the inhibi-
tory MAb 1G3 strongly diminished the amount of intracellular
aﬂibercept. Taken together, preventing the interaction between
FcRn and aﬂibercept (i.e. in the presence of IgG-binding proteins or
inhibitory MAb 1G3) likely resulted in degradation of the Fc fusion
protein, as it would be expected. However, aﬂibercept as well as
bevacizumab are still internalized by iBREC when interaction with
FcRn is inhibited. Therefore, FcRn is likely not required in the
process leading to uptake of aﬂibercept (or bevacizumab) by iBREC
behaving like other sorts of endothelial cells.
Similar to the behavior of the therapeutic antibody bevacizumab
in such experiments, the slower transcytosis of aﬂibercept induced
by serum depletion was associated with a reversible accumulation
of the Fc fusion protein in the fraction of cytoskeleton components,
and aﬂibercept was no longer present in EEA1-positive early
endosomes, suggesting a block of intracellular transport (Deissler
et al., 2016). This might be due to reduced expression of the FcRnor other components of the transport machinery, e.g. the small Ras-
like GTPases Rab11 and Rab4 (Ward et al., 2005). Exosomes staining
positive for FcRn and Rab11, but not for Rab4, are involved in
exocytosis of FcRn-bound IgG in human microvascular endothelial
cells (Ward et al., 2003, 2005): These Rab11þ/Rab4-vesicles are
transported to the plasma membrane where FcRn-bound IgG can
be released by exocytosis at neutral pH. Preliminary data suggest
that expression of Rab11 in iBREC exposed to serum-free culture
medium is indeed reduced (unpublished observation). Block in
intracellular transport of aﬂibercept (and bevacizumab) - likely
bound to residual FcRn - might be due to lack of formation of
Rab11þ-vesicles under these conditions. Proper exocytosis of the
IgG or Fc fusion protein is then hindered. Both Fc-containing pro-
teins are still taken-up by iBREC in the absence of FBS supporting
our assumption that FcRn is likely not involved in their endocytosis.
It seems possible that lack of serum components also prevents
fusion of the early endosomes with lysosomes thereby blocking
degradation of aﬂibercept or bevacizumab, which would be ex-
pected under these conditions. Interestingly, overloading the
transport system of human microvascular endothelial cells with
high amounts of IgG (2.5 mg/ml) resulted in an accumulation of IgG
in the cells; the IgG was localized in EEA1-positive endosomes as
H.L. Deissler et al. / Experimental Eye Research 154 (2017) 39e46 45well as in lysosomes under these conditions (Ward et al., 2003).
Similar results were obtained with lower amounts (250 mg/ml) of a
mutated IgG that was not able to bind to FcRn, suggesting an
important role of the receptor in this process. The ratio of FcRn to
internalized aﬂibercept (or bevacizumab) present in iBREC under
conditions with low serum may simply be still high enough to
protect both proteins from degradation but too low to allow for
further transport. This hypothesis is in accordance with the
observation that human endothelial cells of the lung expressing
high amounts of FcRn internalized more IgG (Goebl et al., 2008).
In addition to transport through a cell monolayer, an IgG might
also be recycled to be released from the same cell side it had
entered. Indeed, at least part of internalized bevacizumab or aﬂi-
bercept seem to leave iBREC at the side of its uptake under certain
conditions. Because data including exact quantiﬁcation are not
available, it cannot be elucidated whether transcytosis or recycling
is the favored route of transport. One can assume that considerable
amounts of an exogenous protein of a type not even present in the
healthy retina need to be cleared rather than recycled under normal
physiological conditions.
IgGs are usually not present in the healthy retina, but the
strongly increased use of intravitreally applied antibodies or Fc
fusion proteins heightens the interest in their intraocular fate and
pharmacokinetics associated with relevant clearance pathways
(Ziemssen et al., 2016). In addition to our ﬁndings concerning REC,
in vitro-studies with retinal pigment epithelium (RPE)-choroid or-
gan cultures revealed that these cells also transport Fc-carrying
proteins bevacizumab and aﬂibercept through their intracellular
space (Dithmer et al., 2016). Internalization of bevacizumab by RPE
cells was markedly decreased when interaction with the FcRn was
impeded, though blocking of the other Fc receptors had no effect
(Dithmer et al., 2016). In addition, both proteins were detected in
vessels of the retina and choroid as well as in the RPE after their
intravitreal injection into the monkey eye, suggesting that all these
ocular structures might be involved in the transport of Fc-
containing proteins out of the eye (Heiduschka et al., 2007;
Schraermeyer and Julien, 2012; Julien et al., 2014). Further studies
however are required to elucidate the relative relevance of clear-
ance of these proteins via posterior routes compared to the pre-
sumably more important release from the vitreous into the
aqueous humor. In these investigations, clearance from the tar-
geted compartments retina and choroid should be distinguished
from overall clearance from the vitreous.
5. Conclusion
In accordance with our conclusions from experiments with
bevacizumab, all results of our current study strongly suggest that
binding of aﬂibercept to the neonatal Fc receptor is crucially
involved at least at some stage in its intracellular trafﬁcking in REC
in vitro: (1) transport is most efﬁcient when FcRn is strongly
expressed and binding of aﬂibercept to FcRn is not inhibited, (2)
uptake is temperature-sensitive and (3) intracellular aﬂibercept is
localized in EEA1-positive early endosomes which harbor the FcRn.
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